-transparent.png){kind=logo}
The effects of eight weeks of treatment with isradipine (1.25 mg twice daily for four weeks, followed by 2.5 mg twice daily for four weeks) on ex vivo platelet function were investigated in ten male patients with hypertension. Systolic and diastolic blood pressures, platelet aggregation in response to adenosine diphosphate (ADP), serum thromboxane B2, and beta-thromboglobulin levels were significantly decreased (P less than .05) at rest before exercise ergometry, during exercise, and at rest after exercise. The platelet count and plasma levels of 6-oxo-prostaglandin F1 alpha (PGF1 alpha) were not affected by isradipine. It is concluded that treatment of hypertension with a compound that lowers blood pressure and inhibits platelet activation may be of clinical benefit when routinely applied in hypertensive patients.
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
January 1988,
European journal of clinical pharmacology,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
February 1991,
American journal of hypertension,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
January 1987,
Journal of cardiovascular pharmacology,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
January 1984,
Acta medica Scandinavica. Supplementum,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
August 1983,
Journal of hypertension,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
January 1967,
Acta medica Scandinavica,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
January 1982,
Revista espanola de cardiologia,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
November 1980,
Casopis lekaru ceskych,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
January 1980,
Cor et vasa,
P Fitscha, and
I Virgolini, and
F Rauscha, and
H Sinzinger
January 1980,
Postgraduate medical journal,
